Should I buy Acadia Healthcare (ACHC) stock or is it too late?

Acadia Healthcare · Health Care · price $30
Logo Acadia HealthcareSee the full Acadia Healthcare (ACHC) profile
⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Guggenheim69% of its targets hit on this sector (49 calls tested). It aims for $39 (+29 %), call made on July 31, 2026, maturing on July 31, 2027 (28 d ago).

The 3 reliable analysts $39+29 %
The 5 other firms $32+5.9 %
How to read it: the 3 reliable firms are not filtered by optimism — 2 aim above the price, 1 below, hence their $39 median. “The 5 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Acadia Healthcare

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.
Firm% rightGain vs sectorCallsAims for
Raymond James67 %+43.2 %9$30 -1%
B of A Securities71 %+5.7 %7$13 -57%
UBS43 %-0.3 %7$39 +29%
Deutsche Bank33 %-16.2 %6$20 -34%
RBC Capital9 %-34.3 %11$31 +3%
Barclays12 %-51.2 %8$32 +6%
BMO Capital67 %+36.6 %6
Citigroup40 %+16.0 %5
In short — Should you invest in Acadia Healthcare? Is it too late, still worth it? Analysts are fairly positive (75% buy, median target $34, i.e. +13%). But it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

  • 75% of analysts rate it a buy (Buy consensus, 8 ratings) — a sign of market conviction.
  • Median price target $34, i.e. +13% from the current price ($30).

⚠️ Reasons to hesitate

  • Even the most reliable firm on ACHC, Jefferies (75% hit rate, 4 scored calls), only targets $30 (call made on June 3, 2026, maturing on June 3, 2027) (-1%) in its most recent call, and $15 (call made on January 22, 2026, maturing on January 22, 2027) (-50%) in the one coming due soonest. The stock may already have run past its target.
  • The consensus is not unanimous: of 8 ratings, 2 are neutral.
  • A 12-month target is not a guaranteed path: the price can fall in the meantime.
  • No dividend: your return depends only on price appreciation.

The analyst consensus on ACHC

Median target $34 (+13%) · 8 ratings · Buy consensus

Strong Buy00%
Buy675%
Hold225%
Sell00%
Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Acadia Healthcare now?

We won't decide for you. The facts: 75% of analysts rate it a buy, median target $34 (+13%), and Jefferies (most reliable on ACHC, 75%) targets $30. Weigh that against valuation. This is not personalized advice.

Is it too late to invest in Acadia Healthcare?

Not according to analysts: the median target ($34) is still +13% above the current price ($30) (most reliable on ACHC: Jefferies, 75%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Acadia Healthcare still worth investing in?

It depends on the gap between the price ($30) and its estimated value: analysts target $34 on median (+13%), with 75% buys (most reliable on ACHC: Jefferies, 75%). Cross-check with their real reliability on ACHC and the cautions above. Information, not advice.

What's the main risk in buying ACHC?

Even the most reliable firm on ACHC, Jefferies (75% hit rate, 4 scored calls), only targets $30 (call made on June 3, 2026, maturing on June 3, 2027) (-1%) in its most recent call, and $15 (call made on January 22, 2026, maturing on January 22, 2027) (-50%) in the one coming due soonest. The stock may already have run past its target.

→ Go deeper: the full Acadia Healthcare profile (consensus, analyst reliability, price target, performance).

JPI AI Analyst AI assistant · JPI Invest
Answers based on the tool’s data · not financial advice · full version (free)